Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and weaknesses. Prasugrel and ticagrelor are more potent inhibitors of platelet aggregation and were shown to be superior to clopidogrel in ...
Existing approaches for personalization of antithrombotic prescriptions will be reviewed using practical examples for P2Y12 inhibitors and direct oral anticoagulants. The review will additionally focus on the existing PBPK and POPPK models for these two categories of drugs. Lastly, we address potential ...
Pharmacokinetic drug interactions that are mediated by CYP3A4 and/or P-gp, have an influence within the framework of antithrombotic therapy not only on the new direct oral anticoagulants but also on the important platelet aggrega-tion inhibitors of the P2Y12 antagonists type. In such cases the ...